{"id":7725,"date":"2024-08-22T16:32:19","date_gmt":"2024-08-22T09:32:19","guid":{"rendered":"https:\/\/thaipropertynews.com\/feeds\/?p=7725"},"modified":"2024-08-22T16:32:19","modified_gmt":"2024-08-22T09:32:19","slug":"telix-2024-half-year-results-strong-commercial-revenue-and-profit-growth-to-support-strategic-priorities","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=7725","title":{"rendered":"Telix 2024 Half-Year Results: Strong Commercial Revenue and Profit Growth to Support Strategic Priorities"},"content":{"rendered":"

MELBOURNE, Australia<\/span><\/span>, Aug. 22, 2024<\/span><\/span> \/PRNewswire\/ — Telix Pharmaceuticals\u00a0Limited (ASX: TLX,\u00a0Telix, the Company) today announces its financial results for the half-year ended 30 June 2024<\/span>. All figures are in AU$ unless otherwise stated.[1]<\/p>\n

\n<\/div>\n

H1 2024 financial highlights<\/p>\n

Total Group revenue of $364.0 million<\/span>, an increase of 65% compared to H1 2023, reflecting continued growth in sales of its prostate cancer imaging agent, Illuccix\u00ae in the United States<\/span> (U.S.), now in its second full year of commercial sales. Net profit after tax of $29.7 million<\/span> compared to a net loss of $14.3 million<\/span> in H1 2023. Gross margin improved to 66% (compared to 63% in H1 2023), supported by stable selling price of Illuccix\u00ae and disciplined cost control. Adjusted earnings before interest, tax, depreciation, and amortisation (Adjusted EBITDA) of $57.5 million<\/span>, an increase of $22.8 million<\/span> or 66%, when compared to $34.7 million<\/span> in H1 2023. Adjusted earnings before interest, tax, depreciation, amortisation and research and development (Adjusted EBITDAR) of $137.1 million<\/span>, a significant uplift from $81.3 million<\/span> in H1 2023, demonstrating the profitability of the commercial organisation. Net cash generated from operating activities of $39.1 million<\/span> (compared to $13.3 million<\/span> in H1 2023), primarily from sales of Illuccix\u00ae. Closing cash balance was $118.8 million<\/span> as at 30 June 2024<\/span>. Subsequent to the reporting period, Telix completed a convertible bond financing, raising $650.0 million<\/span> (before costs). Telix reaffirms its full year 2024 revenue guidance of US$490M<\/span> to US$510M<\/span> ($745 million<\/span> to $776 million<\/span> at current exchange rates), representing a ~48-54% increase on FY 2023. Telix also confirms previously advised guidance for R&D expenditure remains unchanged[2]. <\/p>\n

H1 2024 operational highlights<\/p>\n

Positive efficacy data generated by the ProstACT SELECT (TLX591) study, and proof-of-concept in the CUPID (TLX592) study reinforce the clinical potential and differentiation of the Company’s beta and alpha prostate cancer therapy programs. For the Phase III ProstACT GLOBAL trial (TLX591), the Investigational New Drug application was cleared by the U.S. Food and Drug Administration (FDA) and site activation commenced in the U.S. Expansion of the commercial precision medicine (diagnostic imaging) portfolio: Regulatory filing of a New Drug Application (NDA) for a new PSMA-PET[3] product (TLX007-CDx) accepted by the FDA. Regulatory filings for two additional new products: TLX101-CDx (Pixclara\u00ae[4] for imaging of glioma) and TLX250- CDx (Zircaix\u00ae[4] for imaging of kidney cancer) expected in Q3 2024, and Q4 2024[5], respectively. Illuccix\u00ae European Union (EU) and United Kingdom<\/span> (UK) submissions progressing in line with expectations and in accordance with guidance to industry. All questions raised by the German Federal Institute for Drugs and Medical Devices (Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte, BfArM) as EU competent authority during standard review “clock-stop” period have been addressed. The UK Medicines & Healthcare Products Regulatory Agency (MHRA) regulator’s assessment report has been received with no substantive issues raised. Decisions expected in H2 2024. Illuccix\u00ae submission with the Brazilian Health Regulatory Agency (Agencia Nacional de Vigilancia Sanitaria, ANVISA) in the final stages of review with an approval decision anticipated during Q3 2024 based on current information. Approval is expected, however regulator has been experiencing strike action. Completion of the ARTMS\u00a0and\u00a0IsoTherapeutics\u00a0acquisitions\u00a0further\u00a0enhance ongoing\u00a0vertical\u00a0integration\u00a0strategy, delivering greater control over supply chain and additional self-sufficiency and capabilities in manufacturing, particularly for gallium-68 (68Ga) and zirconium-89 (89Zr) to support near-term revenue and margin growth. <\/p>\n

Dr\u00a0Christian\u00a0Behrenbruch, Managing Director and Group Chief Executive Officer, commented on the result:<\/p>\n

“Telix continues to grow revenue from Illuccix\u00ae, increase gross profit margin and manage costs effectively, while investing\u00a0for\u00a0future\u00a0growth. Our\u00a0achievements\u00a0in\u00a0the\u00a0first half\u00a0of\u00a02024\u00a0have\u00a0created value\u00a0for\u00a0shareholders\u00a0and\u00a0positioned the Company for success on multiple fronts. Building on our commercial success with Illuccix\u00ae, we are focused on expanding the near-term opportunity in precision medicine diagnostics with three new products planned for launch in 2025,\u00a0subject to regulatory\u00a0approval.\u00a0At\u00a0the\u00a0same\u00a0time,\u00a0new\u00a0efficacy\u00a0data from\u00a0the\u00a0ProstACT SELECT trial has reinforced the therapeutic potential of TLX591 \u2013 our Phase III asset for prostate cancer therapy, while we have a number of additional significant clinical milestones ahead across our therapeutic pipeline.<\/p>\n

“We\u00a0also\u00a0continue to\u00a0build\u00a0out\u00a0our\u00a0internal manufacturing\u00a0capability,\u00a0which we\u00a0believe\u00a0is\u00a0a\u00a0competitive\u00a0advantage\u00a0for\u00a0our radiopharmaceutical\u00a0supply chain\u00a0and\u00a0ability to\u00a0deliver\u00a0patient doses\u00a0globally.\u00a0Telix’s successful\u00a0$650\u00a0million convertible bond offering will facilitate our ambitions in this regard, while also positioning us to accelerate clinical development on key programs and capitalise on potential strategic M&A opportunities.<\/p>\n

“We believe the radiopharmaceutical sector is at an inflection point and Telix has the proven commercial ability, clinical experience\u00a0and\u00a0balance sheet\u00a0strength\u00a0to\u00a0advance\u00a0our\u00a0leading-edge\u00a0theranostic\u00a0pipeline.\u00a0With\u00a0a\u00a0proven\u00a0revenue stream and a clear path to future business growth, Telix is positioned at the vanguard of this fast-growing field.”<\/p>\n

Investor call<\/p>\n

An\u00a0investor webcast\u00a0will\u00a0be\u00a0held\u00a0at\u00a09.00am\u00a0AEST on\u00a0Friday 23\u00a0August\u00a02024\u00a0(7.00pm\u00a0EDT,\u00a0Thursday\u00a022\u00a0August\u00a02024).<\/p>\n

Participants\u00a0can\u00a0register for\u00a0the\u00a0webcast\u00a0and\u00a0find\u00a0audio\u00a0call\u00a0details\u00a0at\u00a0the\u00a0following link:\u00a0https:\/\/s1.c-conf.com\/<\/a> diamondpass\/10041010-puhyt.html<\/a><\/p>\n

About\u00a0Telix Pharmaceuticals\u00a0Limited<\/p>\n

Telix\u00a0is\u00a0a\u00a0biopharmaceutical\u00a0company focused\u00a0on\u00a0the\u00a0development\u00a0and\u00a0commercialisation\u00a0of\u00a0therapeutic\u00a0and\u00a0diagnostic radiopharmaceuticals\u00a0and\u00a0associated\u00a0medical\u00a0devices.\u00a0Telix\u00a0is\u00a0headquartered\u00a0in\u00a0Melbourne,\u00a0Australia,\u00a0with\u00a0international operations in the United States<\/span>, Europe<\/span> (Belgium<\/span> and Switzerland<\/span>), and Japan<\/span>. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases.<\/p>\n

Telix\u00a0is\u00a0listed\u00a0on\u00a0the\u00a0Australian\u00a0Securities\u00a0Exchange\u00a0(ASX:\u00a0TLX).<\/p>\n

Telix’s\u00a0lead\u00a0imaging product,\u00a0gallium-68\u00a0(68Ga)\u00a0gozetotide\u00a0injection,\u00a0(also\u00a0known\u00a0as\u00a068Ga\u00a0PSMA-11\u00a0and\u00a0marketed under the brand name Illuccix\u00ae), has been approved by the U.S. Food and Drug Administration (FDA)[6], by the Australian Therapeutic Goods Administration (TGA)[7], and by Health Canada[8]. No other\u00a0Telix product has received a marketing authorisation in any jurisdiction.<\/p>\n

Visit\u00a0www.telixpharma.com<\/a>\u00a0for\u00a0further information\u00a0about\u00a0Telix, including\u00a0details\u00a0of\u00a0the\u00a0latest share\u00a0price,\u00a0announcements made\u00a0to the\u00a0ASX,\u00a0investor and\u00a0analyst\u00a0presentations,\u00a0news\u00a0releases,\u00a0event details\u00a0and\u00a0other publications\u00a0that\u00a0may\u00a0be\u00a0of interest. You can also follow Telix on X<\/a> and LinkedIn<\/a>.<\/p>\n

1].\u00a0\u00a0 Conversion to AU$ is at the exchange rate on the relevant transaction date. The average exchange rate realised during the period was AU$1 = US$0.66<\/span>; AU$1 = \u20ac0.58.
[2].\u00a0\u00a0 Telix\u00a0ASX\u00a0disclosures\u00a018\u00a0July\u00a02024\u00a0and\u00a022\u00a0February\u00a02024.\u00a0Revenue\u00a0guidance is\u00a0based\u00a0on\u00a0approved\u00a0products in\u00a0jurisdictions\u00a0with\u00a0a\u00a0marketing authorisation.\u00a0Illuccix\u00ae\u00a0has\u00a0received\u00a0a\u00a0marketing authorisation in Australia<\/span>, Canada<\/span> and the U.S.
[3].\u00a0\u00a0 Imaging of prostate-specific membrane antigen with positron emission tomography.
[4].\u00a0\u00a0 Brand name subject to final regulatory approval.
[5].\u00a0\u00a0 FDA has requested further validation for the TLX250-CDx Biologics License Application (BLA) filing\u00a0to\u00a0advance to\u00a0full\u00a0review. Telix\u00a0ASX disclosure 31 July 2024<\/span>.
[6].\u00a0\u00a0 Telix\u00a0ASX disclosure\u00a020\u00a0December\u00a02021.
[7].\u00a0\u00a0 Telix\u00a0ASX disclosure\u00a02\u00a0November\u00a02021.
[8].\u00a0\u00a0 Telix\u00a0ASX\u00a0disclosure\u00a014\u00a0October\u00a02022.<\/span><\/p>\n

Telix Investor\u00a0Relations<\/p>\n

Ms.\u00a0Kyahn Williamson
Telix Pharmaceuticals\u00a0Limited
SVP\u00a0Investor\u00a0Relations and\u00a0Corporate\u00a0Communications Email:
kyahn.williamson@telixpharma.com<\/a><\/p>\n

This\u00a0announcement\u00a0has\u00a0been\u00a0authorised\u00a0for\u00a0release\u00a0by\u00a0the\u00a0Telix Pharmaceuticals\u00a0Limited Board\u00a0of\u00a0Directors<\/p>\n

Legal Notices<\/p>\n

You\u00a0should\u00a0read\u00a0this\u00a0announcement\u00a0together\u00a0with\u00a0our\u00a0risk\u00a0factors, as\u00a0disclosed\u00a0in\u00a0our\u00a0most\u00a0recently\u00a0filed\u00a0reports\u00a0with\u00a0the Australian Securities Exchange (ASX) or on our website.<\/p>\n

The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States<\/span>. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.<\/p>\n

This announcement may contain forward-looking statements that relate to anticipated future events, financial performance,\u00a0plans, strategies\u00a0or\u00a0business developments.\u00a0Forward-looking\u00a0statements\u00a0can\u00a0generally\u00a0be\u00a0identified\u00a0by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast”<\/p>\n

and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance\u00a0or\u00a0achievements\u00a0to\u00a0differ\u00a0materially\u00a0from\u00a0any\u00a0future results,\u00a0levels\u00a0of\u00a0activity,\u00a0performance\u00a0or\u00a0achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s<\/p>\n

business\u00a0and\u00a0operations\u00a0in\u00a0the\u00a0future\u00a0and\u00a0there\u00a0can\u00a0be\u00a0no\u00a0assurance\u00a0that\u00a0any\u00a0of\u00a0the\u00a0assumptions\u00a0will\u00a0prove\u00a0to\u00a0be\u00a0correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about:<\/p>\n

the initiation, timing, progress and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialisation of Telix’s product candidates, if or when they have been approved; Telix’s\u00a0ability\u00a0to\u00a0obtain\u00a0an\u00a0adequate\u00a0supply of\u00a0raw\u00a0materials\u00a0at\u00a0reasonable\u00a0costs\u00a0for\u00a0its\u00a0products\u00a0and\u00a0product\u00a0candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating\u00a0to\u00a0Telix’s competitors\u00a0and\u00a0industry; and\u00a0the\u00a0pricing\u00a0and\u00a0reimbursement\u00a0of\u00a0Telix’s\u00a0product candidates,\u00a0if\u00a0and\u00a0after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.<\/p>\n

Telix\u00a0uses\u00a0various non-IFRS\u00a0information\u00a0to\u00a0reflect\u00a0its\u00a0underlying\u00a0performance.\u00a0For\u00a0further\u00a0information,\u00a0the\u00a0reconciliation of non-IFRS financial information to Telix’s statutory measures, reasons for usefulness and calculation methodology, please refer to the Alternative performance measures section in Telix’s Annual Report.<\/p>\n

\u00a92024\u00a0Telix\u00a0Pharmaceuticals\u00a0Limited.\u00a0The\u00a0Telix\u00a0Pharmaceuticals\u00ae,\u00a0Illuccix\u00ae,\u00a0Pixclara\u00ae[4] and Zircaix\u00ae[4] names and logos are trademarks of Telix Pharmaceuticals Limited and its affiliates \u2013 all rights reserved.<\/p>","protected":false},"excerpt":{"rendered":"

<\/p>\n

MELBOURNE, Australia<\/span><\/span>, Aug. 22, 2024<\/span><\/span> \/PRNewswire\/ — Telix Pharmaceuticals\u00a0Limited (ASX: TLX,\u00a0Telix, the Company) today announces its financial results for the half-year ended 30 June 2024<\/span>. All figures are in AU$ unless otherwise stated.[1]<\/p>\n

\n<\/div>\n

H1 2024 financial highlights<\/p>\n

Total Group revenue of $364.0 million<\/span>, an increase of 65% compared to H1 2023, reflecting continued growth in sales of its prostate cancer imaging agent, Illuccix\u00ae in the United States<\/span> (U.S.), now in its second full year of commercial sales. Net profit after tax of $29.7 million<\/span> compared to a net loss of $14.3 million<\/span> in H1 2023. Gross margin improved to 66% (compared to 63% in H1 2023), supported by stable selling price of Illuccix\u00ae and disciplined cost control. Adjusted earnings before interest, tax, depreciation, and amortisation (Adjusted EBITDA) of $57.5 million<\/span>, an increase of $22.8 million<\/span> or 66%, when compared to $34.7 million<\/span> in H1 2023. Adjusted earnings before interest, tax, depreciation, amortisation and research and development (Adjusted EBITDAR) of $137.1 million<\/span>, a significant uplift from $81.3 million<\/span> in H1 2023, demonstrating the profitability of the commercial organisation. Net cash generated from operating activities of $39.1 million<\/span> (compared to $13.3 million<\/span> in H1 2023), primarily from sales of Illuccix\u00ae. Closing cash balance was $118.8 million<\/span> as at 30 June 2024<\/span>. Subsequent to the reporting period, Telix completed a convertible bond financing, raising $650.0 million<\/span> (before costs). Telix reaffirms its full year 2024 revenue guidance of US$490M<\/span> to US$510M<\/span> ($745 million<\/span> to $776 million<\/span> at current exchange rates), representing a ~48-54% increase on FY 2023. Telix also confirms previously advised guidance for R&D expenditure remains unchanged[2]. <\/p>\n

H1 2024 operational highlights<\/p>\n

Positive efficacy data generated by the ProstACT SELECT (TLX591) study, and proof-of-concept in the CUPID (TLX592) study reinforce the clinical potential and differentiation of the Company’s beta and alpha prostate cancer therapy programs. For the Phase III ProstACT GLOBAL trial (TLX591), the Investigational New Drug application was cleared by the U.S. Food and Drug Administration (FDA) and site activation commenced in the U.S. Expansion of the commercial precision medicine (diagnostic imaging) portfolio: Regulatory filing of a New Drug Application (NDA) for a new PSMA-PET[3] product (TLX007-CDx) accepted by the FDA. Regulatory filings for two additional new products: TLX101-CDx (Pixclara\u00ae[4] for imaging of glioma) and TLX250- CDx (Zircaix\u00ae[4] for imaging of kidney cancer) expected in Q3 2024, and Q4 2024[5], respectively. Illuccix\u00ae European Union (EU) and United Kingdom<\/span> (UK) submissions progressing in line with expectations and in accordance with guidance to industry. All questions raised by the German Federal Institute for Drugs and Medical Devices (Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte, BfArM) as EU competent authority during standard review “clock-stop” period have been addressed. The UK Medicines & Healthcare Products Regulatory Agency (MHRA) regulator’s assessment report has been received with no substantive issues raised. Decisions expected in H2 2024. Illuccix\u00ae submission with the Brazilian Health Regulatory Agency (Agencia Nacional de Vigilancia Sanitaria, ANVISA) in the final stages of review with an approval decision anticipated during Q3 2024 based on current information. Approval is expected, however regulator has been experiencing strike action. Completion of the ARTMS\u00a0and\u00a0IsoTherapeutics\u00a0acquisitions\u00a0further\u00a0enhance ongoing\u00a0vertical\u00a0integration\u00a0strategy, delivering greater control over supply chain and additional self-sufficiency and capabilities in manufacturing, particularly for gallium-68 (68Ga) and zirconium-89 (89Zr) to support near-term revenue and margin growth. <\/p>\n

Dr\u00a0Christian\u00a0Behrenbruch, Managing Director and Group Chief Executive Officer, commented on the result:<\/p>\n

“Telix continues to grow revenue from Illuccix\u00ae, increase gross profit margin and manage costs effectively, while investing\u00a0for\u00a0future\u00a0growth. Our\u00a0achievements\u00a0in\u00a0the\u00a0first half\u00a0of\u00a02024\u00a0have\u00a0created value\u00a0for\u00a0shareholders\u00a0and\u00a0positioned the Company for success on multiple fronts. Building on our commercial success with Illuccix\u00ae, we are focused on expanding the near-term opportunity in precision medicine diagnostics with three new products planned for launch in 2025,\u00a0subject to regulatory\u00a0approval.\u00a0At\u00a0the\u00a0same\u00a0time,\u00a0new\u00a0efficacy\u00a0data from\u00a0the\u00a0ProstACT SELECT trial has reinforced the therapeutic potential of TLX591 \u2013 our Phase III asset for prostate cancer therapy, while we have a number of additional significant clinical milestones ahead across our therapeutic pipeline.<\/p>\n

“We\u00a0also\u00a0continue to\u00a0build\u00a0out\u00a0our\u00a0internal manufacturing\u00a0capability,\u00a0which we\u00a0believe\u00a0is\u00a0a\u00a0competitive\u00a0advantage\u00a0for\u00a0our radiopharmaceutical\u00a0supply chain\u00a0and\u00a0ability to\u00a0deliver\u00a0patient doses\u00a0globally.\u00a0Telix’s successful\u00a0$650\u00a0million convertible bond offering will facilitate our ambitions in this regard, while also positioning us to accelerate clinical development on key programs and capitalise on potential strategic M&A opportunities.<\/p>\n

“We believe the radiopharmaceutical sector is at an inflection point and Telix has the proven commercial ability, clinical experience\u00a0and\u00a0balance sheet\u00a0strength\u00a0to\u00a0advance\u00a0our\u00a0leading-edge\u00a0theranostic\u00a0pipeline.\u00a0With\u00a0a\u00a0proven\u00a0revenue stream and a clear path to future business growth, Telix is positioned at the vanguard of this fast-growing field.”<\/p>\n

Investor call<\/p>\n

An\u00a0investor webcast\u00a0will\u00a0be\u00a0held\u00a0at\u00a09.00am\u00a0AEST on\u00a0Friday 23\u00a0August\u00a02024\u00a0(7.00pm\u00a0EDT,\u00a0Thursday\u00a022\u00a0August\u00a02024).<\/p>\n

Participants\u00a0can\u00a0register for\u00a0the\u00a0webcast\u00a0and\u00a0find\u00a0audio\u00a0call\u00a0details\u00a0at\u00a0the\u00a0following link:\u00a0https:\/\/s1.c-conf.com\/<\/a> diamondpass\/10041010-puhyt.html<\/a><\/p>\n

About\u00a0Telix Pharmaceuticals\u00a0Limited<\/p>\n

Telix\u00a0is\u00a0a\u00a0biopharmaceutical\u00a0company focused\u00a0on\u00a0the\u00a0development\u00a0and\u00a0commercialisation\u00a0of\u00a0therapeutic\u00a0and\u00a0diagnostic radiopharmaceuticals\u00a0and\u00a0associated\u00a0medical\u00a0devices.\u00a0Telix\u00a0is\u00a0headquartered\u00a0in\u00a0Melbourne,\u00a0Australia,\u00a0with\u00a0international operations in the United States<\/span>, Europe<\/span> (Belgium<\/span> and Switzerland<\/span>), and Japan<\/span>. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases.<\/p>\n

Telix\u00a0is\u00a0listed\u00a0on\u00a0the\u00a0Australian\u00a0Securities\u00a0Exchange\u00a0(ASX:\u00a0TLX).<\/p>\n

Telix’s\u00a0lead\u00a0imaging product,\u00a0gallium-68\u00a0(68Ga)\u00a0gozetotide\u00a0injection,\u00a0(also\u00a0known\u00a0as\u00a068Ga\u00a0PSMA-11\u00a0and\u00a0marketed under the brand name Illuccix\u00ae), has been approved by the U.S. Food and Drug Administration (FDA)[6], by the Australian Therapeutic Goods Administration (TGA)[7], and by Health Canada[8]. No other\u00a0Telix product has received a marketing authorisation in any jurisdiction.<\/p>\n

Visit\u00a0www.telixpharma.com<\/a>\u00a0for\u00a0further information\u00a0about\u00a0Telix, including\u00a0details\u00a0of\u00a0the\u00a0latest share\u00a0price,\u00a0announcements made\u00a0to the\u00a0ASX,\u00a0investor and\u00a0analyst\u00a0presentations,\u00a0news\u00a0releases,\u00a0event details\u00a0and\u00a0other publications\u00a0that\u00a0may\u00a0be\u00a0of interest. You can also follow Telix on X<\/a> and LinkedIn<\/a>.<\/p>\n

1].\u00a0\u00a0 Conversion to AU$ is at the exchange rate on the relevant transaction date. The average exchange rate realised during the period was AU$1 = US$0.66<\/span>; AU$1 = \u20ac0.58.
[2].\u00a0\u00a0 Telix\u00a0ASX\u00a0disclosures\u00a018\u00a0July\u00a02024\u00a0and\u00a022\u00a0February\u00a02024.\u00a0Revenue\u00a0guidance is\u00a0based\u00a0on\u00a0approved\u00a0products in\u00a0jurisdictions\u00a0with\u00a0a\u00a0marketing authorisation.\u00a0Illuccix\u00ae\u00a0has\u00a0received\u00a0a\u00a0marketing authorisation in Australia<\/span>, Canada<\/span> and the U.S.
[3].\u00a0\u00a0 Imaging of prostate-specific membrane antigen with positron emission tomography.
[4].\u00a0\u00a0 Brand name subject to final regulatory approval.
[5].\u00a0\u00a0 FDA has requested further validation for the TLX250-CDx Biologics License Application (BLA) filing\u00a0to\u00a0advance to\u00a0full\u00a0review. Telix\u00a0ASX disclosure 31 July 2024<\/span>.
[6].\u00a0\u00a0 Telix\u00a0ASX disclosure\u00a020\u00a0December\u00a02021.
[7].\u00a0\u00a0 Telix\u00a0ASX disclosure\u00a02\u00a0November\u00a02021.
[8].\u00a0\u00a0 Telix\u00a0ASX\u00a0disclosure\u00a014\u00a0October\u00a02022.<\/span><\/p>\n

Telix Investor\u00a0Relations<\/p>\n

Ms.\u00a0Kyahn Williamson
Telix Pharmaceuticals\u00a0Limited
SVP\u00a0Investor\u00a0Relations and\u00a0Corporate\u00a0Communications Email:
kyahn.williamson@telixpharma.com<\/a><\/p>\n

This\u00a0announcement\u00a0has\u00a0been\u00a0authorised\u00a0for\u00a0release\u00a0by\u00a0the\u00a0Telix Pharmaceuticals\u00a0Limited Board\u00a0of\u00a0Directors<\/p>\n

Legal Notices<\/p>\n

You\u00a0should\u00a0read\u00a0this\u00a0announcement\u00a0together\u00a0with\u00a0our\u00a0risk\u00a0factors, as\u00a0disclosed\u00a0in\u00a0our\u00a0most\u00a0recently\u00a0filed\u00a0reports\u00a0with\u00a0the Australian Securities Exchange (ASX) or on our website.<\/p>\n

The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States<\/span>. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.<\/p>\n

This announcement may contain forward-looking statements that relate to anticipated future events, financial performance,\u00a0plans, strategies\u00a0or\u00a0business developments.\u00a0Forward-looking\u00a0statements\u00a0can\u00a0generally\u00a0be\u00a0identified\u00a0by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast”<\/p>\n

and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance\u00a0or\u00a0achievements\u00a0to\u00a0differ\u00a0materially\u00a0from\u00a0any\u00a0future results,\u00a0levels\u00a0of\u00a0activity,\u00a0performance\u00a0or\u00a0achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s<\/p>\n

business\u00a0and\u00a0operations\u00a0in\u00a0the\u00a0future\u00a0and\u00a0there\u00a0can\u00a0be\u00a0no\u00a0assurance\u00a0that\u00a0any\u00a0of\u00a0the\u00a0assumptions\u00a0will\u00a0prove\u00a0to\u00a0be\u00a0correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about:<\/p>\n

the initiation, timing, progress and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialisation of Telix’s product candidates, if or when they have been approved; Telix’s\u00a0ability\u00a0to\u00a0obtain\u00a0an\u00a0adequate\u00a0supply of\u00a0raw\u00a0materials\u00a0at\u00a0reasonable\u00a0costs\u00a0for\u00a0its\u00a0products\u00a0and\u00a0product\u00a0candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating\u00a0to\u00a0Telix’s competitors\u00a0and\u00a0industry; and\u00a0the\u00a0pricing\u00a0and\u00a0reimbursement\u00a0of\u00a0Telix’s\u00a0product candidates,\u00a0if\u00a0and\u00a0after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.<\/p>\n

Telix\u00a0uses\u00a0various non-IFRS\u00a0information\u00a0to\u00a0reflect\u00a0its\u00a0underlying\u00a0performance.\u00a0For\u00a0further\u00a0information,\u00a0the\u00a0reconciliation of non-IFRS financial information to Telix’s statutory measures, reasons for usefulness and calculation methodology, please refer to the Alternative performance measures section in Telix’s Annual Report.<\/p>\n

\u00a92024\u00a0Telix\u00a0Pharmaceuticals\u00a0Limited.\u00a0The\u00a0Telix\u00a0Pharmaceuticals\u00ae,\u00a0Illuccix\u00ae,\u00a0Pixclara\u00ae[4] and Zircaix\u00ae[4] names and logos are trademarks of Telix Pharmaceuticals Limited and its affiliates \u2013 all rights reserved.<\/p>\n

<\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-7725","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/7725","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=7725"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/7725\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=7725"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=7725"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=7725"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}